babytrades_

babytrades_

NASDAQ:NKTX Looking like a technical reversal on the daily chart - MACD, TTM, and MACD look very resilient after a selloff. Analysts set price targets at 15$, indicators seem to match up with this. Earnings in 17 days and mid-year treatment trials could be catalysts to move the price towards this target. Earlier results were promising. Make sure to manage...

babytrades_

NASDAQ:LULU Lululemon Athletica's Q4 performance exceeded expectations, with revenues rising 16% and gross margins growing by 4.3%. However, increased competition and price-conscious consumers have led to a decreased market cap and short-term headwinds. Gross margins remain at 58% leading the industry and showing the prominence of the brand. Lululemon has had...

babytrades_

NASDAQ:NKTX is a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. While highly speculative, the daily charts have presented a purchasing opportunity after a stock offering to raise capital. MACD and TTM Squeeze tend to be reversing, and selling pressure seems to...

babytrades_

I've previously posted my article on the strength and potential of NYSE:ML as a company. My thesis still stands in a mid-term perspective. Additionally, lowering of interest rates and a rotation out of large cap stocks will be very beneficial for Moneylion. On a technical level, MACD, RSI, and TTM Squeeze prove strong on the 4H chart. Additionally, 9...

babytrades_

NYSE:ML Moneylion, a corporation with a highly effective marketing strategy through media and social media influencers, currently has nowhere to go but up. With a CAC (customer acquisition cost) of only 15$, growing EPS and EPS estimate, and a estimation of profitability by 2025 - Moneylion creates a great entry point following the recent pullback. Thesis:...